352 related articles for article (PubMed ID: 31115858)
1. A translational platform PBPK model for antibody disposition in the brain.
Chang HY; Wu S; Meno-Tetang G; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
[TBL] [Abstract][Full Text] [Related]
2. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
3. Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system.
Chang HY; Wu S; Chowdhury EA; Shah DK
J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):337-362. PubMed ID: 35092540
[TBL] [Abstract][Full Text] [Related]
4. PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data.
Wu S; Le Prieult F; Phipps CJ; Mezler M; Shah DK
J Pharmacokinet Pharmacodyn; 2022 Dec; 49(6):579-592. PubMed ID: 36088452
[TBL] [Abstract][Full Text] [Related]
5. Clinical validation of translational antibody PBPK model using tissue distribution data generated with
Liu S; Li Z; Huisman M; Shah DK
J Pharmacokinet Pharmacodyn; 2023 Oct; 50(5):377-394. PubMed ID: 37382712
[TBL] [Abstract][Full Text] [Related]
6. Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs.
Huang HW; Wu S; Chowdhury EA; Shah DK
J Pharmacokinet Pharmacodyn; 2023 Nov; ():. PubMed ID: 37947924
[TBL] [Abstract][Full Text] [Related]
7. Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.
Li Z; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):305-318. PubMed ID: 31028591
[TBL] [Abstract][Full Text] [Related]
8. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
Khot A; Tibbitts J; Rock D; Shah DK
AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
[TBL] [Abstract][Full Text] [Related]
9. Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human.
Ball K; Bouzom F; Scherrmann JM; Walther B; Declèves X
Biopharm Drug Dispos; 2014 Nov; 35(8):485-99. PubMed ID: 25044007
[TBL] [Abstract][Full Text] [Related]
10. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
11. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
Glassman PM; Chen Y; Balthasar JP
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
[TBL] [Abstract][Full Text] [Related]
12. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
[TBL] [Abstract][Full Text] [Related]
13. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
Varkhede N; Forrest ML
J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
[TBL] [Abstract][Full Text] [Related]
14. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.
Hu S; D'Argenio DZ
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362
[TBL] [Abstract][Full Text] [Related]
15. Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits.
Bussing D; K Shah D
J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):597-612. PubMed ID: 32876799
[TBL] [Abstract][Full Text] [Related]
16. Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human.
Wong YC; Centanni M; de Lange ECM
J Clin Pharmacol; 2019 May; 59(5):731-747. PubMed ID: 30676661
[TBL] [Abstract][Full Text] [Related]
17. Translation of Monoclonal Antibodies Pharmacokinetics from Animal to Human Using Physiologically Based Modeling in Open Systems Pharmacology (OSP) Suite: A Retrospective Analysis of Bevacizumab.
Pasquiers B; Benamara S; Felices M; Ternant D; Declèves X; Puszkiel A
Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631343
[TBL] [Abstract][Full Text] [Related]
18. A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data.
Jones HM; Zhang Z; Jasper P; Luo H; Avery LB; King LE; Neubert H; Barton HA; Betts AM; Webster R
CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):738-747. PubMed ID: 31464379
[TBL] [Abstract][Full Text] [Related]
19. Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis.
Chang HY; Wu S; Li Y; Zhang W; Burrell M; Webster CI; Shah DK
MAbs; 2021; 13(1):1874121. PubMed ID: 33499723
[TBL] [Abstract][Full Text] [Related]
20. Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.
Singh AP; Krzyzanski W; Martin SW; Weber G; Betts A; Ahmad A; Abraham A; Zutshi A; Lin J; Singh P
AAPS J; 2015 Mar; 17(2):389-99. PubMed ID: 25445845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
